medcelerator · clinician one-pager
First FDA-Approved Treatment for MCT8 Peripheral Thyrotoxicosis
Emcitate (tiratricol) — dispersible tablets for peripheral thyrotoxicosis in MCT8 deficiency
FDA Approved · United States, European Union · September 22, 2026
Condition: MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)
Who this is for
This is for people living with MCT8 deficiency (Allan-Herndon-Dudley syndrome) — and the caregivers who help them — who need a realistic route to tiratricol. It explains the first FDA-approved US treatment for peripheral thyrotoxicosis (Novel #45, 28 Sep 2026), the retained EU authorisation since 12 Feb 2025, USPI weight-banded start and titration, LC-MS/MS T3 monitoring honesty, and the company US commercial path (RareLink / PANTHERx, expected availability ~8–10 weeks) — without treating peripheral T3 control as a cure for brain under-development, or claiming Canadian authorisation. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency
European Union · Prescription
EU prescription (EC marketing authorisation)
https://www.ema.europa.eu/en/medicines/human/EPAR/emcitate
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/emcitate-tiratricol-mct8